DNLI vs FITB · rev $3.6M vs P/E 17, rev $3.37B
Denali Therapeutics Inc (DNLI) versus Fifth Third Bancorp (FITB) — a side-by-side from cached financials, not a winner call.
Denali Therapeutics Inc (DNLI) is a biotechnology company listed on US.
Fifth Third Bancorp (FITB) is a banks - regional company listed on US.
Latest reported DNLI revenue for 2026-06-30 was $3.6M. Net income was -$256.0M. DNLI currently screens at market cap $2.11B.
Latest reported FITB revenue for 2026-06-30 was $3.37B. Net income was $801.0M. Revenue was up 13.5% from 2026-03-31 to 2026-06-30. FITB currently screens at market cap $45.25B and trailing P/E 16.8.
DNLI currently screens at market cap $2.11B. FITB currently screens at market cap $45.25B and trailing P/E 16.8.
Not investment advice. Open the DNLI and FITB stock pages for the full models.
Not investment advice.